Compare CVRX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | KRRO |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 150.0M |
| IPO Year | 2021 | 2019 |
| Metric | CVRX | KRRO |
|---|---|---|
| Price | $5.86 | $12.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.50 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 268.9K | 208.0K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,651,000.00 | $6,392,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.45 | ★ 181.46 |
| 52 Week Low | $4.37 | $5.20 |
| 52 Week High | $11.30 | $55.89 |
| Indicator | CVRX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 54.41 |
| Support Level | $5.06 | $10.32 |
| Resistance Level | $5.95 | $14.10 |
| Average True Range (ATR) | 0.33 | 1.25 |
| MACD | 0.12 | 0.21 |
| Stochastic Oscillator | 100.00 | 52.89 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.